Last-Chance drug access for tough lung cancer cases
NCT ID NCT06841874
Summary
This program provided access to the experimental drug taletrectinib for patients with advanced ROS1-positive lung cancer who had run out of approved treatment options and couldn't join regular clinical trials. The program was designed for people whose cancer had spread and who couldn't take standard medications like crizotinib or entrectinib. Doctors could request this treatment for patients they believed might benefit when no other options remained.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.